These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 3969876)

  • 1. Bretylium: relations between plasma concentrations and pharmacologic actions in high-frequency ventricular arrhythmias.
    Duff HJ; Roden DM; Yacobi A; Robertson D; Wang T; Maffucci RJ; Oates JA; Woosley RL
    Am J Cardiol; 1985 Feb; 55(4):395-401. PubMed ID: 3969876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the adrenergic nerve terminal in digitalis-induced cardiac toxicity: a study of the effects of pharmacological and surgical denervation.
    Lathers CM; Gerard-Ciminera JL; Baskin SI; Krusz JC; Kelliher GJ; Goldberg PB; Roberts J
    J Cardiovasc Pharmacol; 1982; 4(1):91-8. PubMed ID: 6176806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bretylium tosylate: profile of the only available class III antiarrhythmic agent.
    Anderson JL
    Clin Ther; 1985; 7(2):205-24. PubMed ID: 3886143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac arrhythmias produced by bretylium in cats anesthetized with halothane.
    Condouris GA; Ortiz J; Lyness W
    Eur J Pharmacol; 1979 Apr; 55(1):93-7. PubMed ID: 35358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bretylium tosylate: a newly available antiarrhythmic drug for ventricular arrhythmias.
    Heissenbuttel RH; Bigger JT
    Ann Intern Med; 1979 Aug; 91(2):229-38. PubMed ID: 380436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of chronic canine ventricular tachyarrhythmias with bretylium tosylate.
    Patterson E; Gibson JK
    Circulation; 1981 Nov; 64(5):1045-50. PubMed ID: 7285294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ischemia-induced conduction delay and ventricular arrhythmias: comparative electropharmacology of bethanidine sulfate and bretylium tosylate.
    Kabell G
    J Cardiovasc Pharmacol; 1989 Mar; 13(3):471-82. PubMed ID: 2471895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bretylium (Bretylol) for ventricular arrhythmias.
    Med Lett Drugs Ther; 1978 Dec; 20(24):105-6. PubMed ID: 713969
    [No Abstract]   [Full Text] [Related]  

  • 9. The antiarrhythmic and antifibrillatory actions of bretylium and its o-iodobenzyl trimethylammonium analog, UM-360.
    Kniffen FJ; Lomas TE; Counsell RE; Lucchesi BR
    J Pharmacol Exp Ther; 1975 Jan; 192(1):120-8. PubMed ID: 1123718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of the effect of bretylium on the ventricular fibrillation threshold in dogs.
    Euler DE; Scanlon PJ
    Am J Cardiol; 1985 May; 55(11):1396-401. PubMed ID: 3993577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The action of reserpine, 6-hydroxydopamine, and bretylium on digitalis-induced cardiotoxicity.
    Lathers CM; Gerard-Ciminera JL; Baskin SI; Krusz JC; Kelliher GJ; Roberts J
    Eur J Pharmacol; 1981 Dec; 76(4):371-9. PubMed ID: 6799304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paradoxical ventricular tachycardia and fibrillation after intravenous bretylium therapy. Report of two cases.
    Anderson JL; Popat KD; Pitt B
    Arch Intern Med; 1981 May; 141(6):801-2. PubMed ID: 7235792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe hypotension due to the use of bretylium for postcardiotomy ventricular arrhythmias.
    Kron IL; Nolan SP
    Ann Thorac Surg; 1983 Mar; 35(3):271-3. PubMed ID: 6600915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrophysiologic testing of bretylium tosylate in sustained ventricular tachycardia.
    Bauernfeind RA; Hoff JV; Swiryn S; Palileo E; Strasberg B; Scagliotti D; Rosen KM
    Am Heart J; 1983 Jun; 105(6):973-80. PubMed ID: 6858846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bretylium tosylate: a review.
    Bryan CK; Darby MH
    Am J Hosp Pharm; 1979 Sep; 36(9):1189-92. PubMed ID: 386786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bretylium: a prototype for future development of antidysrhythmic agents.
    Patterson E; Lucchesi BR
    Am Heart J; 1983 Aug; 106(2):426-31. PubMed ID: 6869235
    [No Abstract]   [Full Text] [Related]  

  • 17. Electrophysiologic effects of bretylium tosylate on the canine heart during coronary artery occlusion and reperfusion.
    Gibson JK; Stewart JR; Li YP; Lucchesi BR
    J Cardiovasc Pharmacol; 1983; 5(4):517-24. PubMed ID: 6193345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Competitive inhibition of acetylcholinesterase by bretylium: possible mechanism for its induction of norepinephrine release.
    Schreiber G; Sokolovsky M
    J Cardiovasc Pharmacol; 1985; 7(6):1065-8. PubMed ID: 2418289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure of bretylium to suppress inducible ventricular tachycardia.
    Greene HL; Werner JA; Gross BW; Sears GK
    Am Heart J; 1983 May; 105(5):717-21. PubMed ID: 6846114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of bretylium and clofilium on dispersion of refractoriness and vulnerability to ventricular fibrillation in the ischemic feline heart.
    Kowey PR; Friehling TD; O'Connor KM; Wetstein L; Kelliher GJ
    Am Heart J; 1985 Aug; 110(2):363-70. PubMed ID: 4025111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.